Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Comparison between HuT78 parental and romidpepsin-selected cell lines


ABSTRACT: Gene expression values were determined for HuT78 parental cells and cells selected with romidpesin in the presence of P-glycoprotein inhibitors. HuT78 DpVp35 cells are maintained in 35 ng/ml romidepsin with 2.5 µg/ml verapamil and HuT78 DpP100 cells are maintained in 100 ng/ml romidepsin with 1 µM valspodar To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the presence of P-glycoprotein (Pgp) inhibitors to prevent transporter upregulation. Resistant sublines were 250- to 385-fold resistant to romidepsin and were resistant to apoptosis induced by apicidin, entinostat, panobinostat, belinostat and vorinostat. A custom Taqman array identified increased insulin receptor (INSR) gene expression; immunoblot analysis confirmed increased expression and a 4- to 8-fold increase in mitogen activated protein kinase (MAPK) kinase (MEK) phosphorylation in resistant cells compared to parental cells. Resistant cells were exquisitely sensitive to MEK inhibitors and apoptosis correlated with restoration of proapoptotic Bim. Romidepsin combined with MEK inhibitors yielded greater apoptosis in cells expressing mutant KRAS compared to romidepsin treatment alone. Gene expression analysis of samples obtained from patients with CTCL enrolled on the NCI1312 Phase II study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathway by romidepsin. Immunohistochemical analysis of Bim expression demonstrated decreased expression in some skin biopsies at disease progression. These findings implicate increased activation of MEK and decreased Bim expression as a resistance mechanism to HDIs, supporting combination of romidepsin with MEK inhibitors in clinical trials. Gene expression in resistant lines was compared to parental lines

ORGANISM(S): Homo sapiens

SUBMITTER: Robert Robey 

PROVIDER: E-GEOD-45018 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

Chakraborty Arup R AR   Robey Robert W RW   Luchenko Victoria L VL   Zhan Zhirong Z   Piekarz Richard L RL   Gillet Jean-Pierre JP   Kossenkov Andrew V AV   Wilkerson Julia J   Showe Louise C LC   Gottesman Michael M MM   Collie Nathan L NL   Bates Susan E SE  

Blood 20130326 20


To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the presence of P-glycoprotein inhibitors to prevent transporter upregulation. Resistant sublines were 250- to 385-fold resistant to romidepsin and were resistant to apoptosis induced by apicidin, entinostat, panobinostat, belinostat, and vorinostat. A custom TaqMan array identified increased insulin receptor (INSR) gene expression; imm  ...[more]

Similar Datasets

2013-03-12 | GSE45018 | GEO
2017-08-01 | GSE99015 | GEO
2014-04-29 | E-GEOD-57122 | biostudies-arrayexpress
2014-04-29 | GSE57122 | GEO
2022-05-08 | GSE130917 | GEO
2015-07-01 | E-GEOD-59179 | biostudies-arrayexpress
2022-02-28 | GSE179433 | GEO
2012-10-01 | E-GEOD-37699 | biostudies-arrayexpress
2024-01-26 | PXD045686 | Pride
2019-09-20 | GSE137725 | GEO